GW-501516 vs MK-2866 for weight loss
Short answer: For weight loss, users rate them about the same: 86% report improvement with GW-501516 (50 reports) and 89% with MK-2866 (79 reports).
GW-501516 has 0 meta-analyses and 0 randomized trials on PubMed; MK-2866 has 0 and 0.
Based on 307 reports about GW-501516 and 603 about MK-2866. Not medical advice.
| GW-501516 Substance | MK-2866 SARM | |
|---|---|---|
| User score | 46 | 33 |
| Verdict | Mostly positive | Mixed |
| Positive of reports that state an outcome | 64% | 39% |
| Reports | 307 | 603 |
| Research | DResearch: None | DResearch: None |
| Meta-analyses / RCTs | 0 / 0 | 0 / 0 |
| Mainly used for | ||
| Weight loss % reporting improvement | 86% (50) | 89% (79) |
| Appetite % reporting improvement | 50% (4) | 62% (8) |
| Focus % reporting improvement | — | 71% (7) |
| Energy % reporting improvement | 95% (19) | 54% (37) |
| Sleep % reporting improvement | 0% (2) | 20% (20) |
| Anxiety % reporting improvement | — | 33% (9) |
| Mood % reporting improvement | 100% (2) | 62% (48) |
| Performance % reporting improvement | 93% (71) | 87% (189) |
| Recovery % reporting improvement | 100% (3) | 97% (60) |
| Pain & inflammation % reporting improvement | — | 70% (27) |
| Libido % reporting improvement | — | 31% (45) |
| Hormones % reporting improvement | — | 4% (82) |
| Heart & lipids % reporting improvement | 89% (19) | 0% (8) |
| Skin & hair % reporting improvement | — | 33% (6) |
| Longevity % reporting improvement | 50% (2) | — |
| Common side effects | cancer risk, acne, fatigue, brain fog | suppression, fatigue, insomnia, headache |
| Typical dose reported | 20 mg | Not listed |
MK-2866Full MK-2866 profile →
What a user said
“Ostarine suppresses your natural testosterone just like an aas would”
Related comparisons
Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate